Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co's (NYSE:LLY), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs shortage list.
Hims & Hers Health Inc (紐交所:HIMS)股票週四交易走低，可能與禮來公司(NYSE:LLY)的走勢產生共鳴，此前美國食品和藥物管理局將其從減肥和糖尿病藥物短缺名單中移除。
What Happened: The FDA said in a statement late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound can now keep up with current demand.
事件經過：FDA在週三晚間的一份聲明中表示，禮來公司的治療糖尿病的Mounjaro和減肥藥物Zepbound的供應現在可以跟上當前的需求。
Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.
Mounjaro自2022年底以來一直在監管機構的短缺名單上，而Zepbound自4月以來一直在該名單上。
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.
「FDA已經確認與藥品製造商溝通，他們所述的產品供應能力和製造能力可以滿足目前和預期的國家需求。患者和開藥者仍可能在這些產品從製造商和分銷商經銷至當地藥房的過程中見到間歇性的局部供應中斷。」FDA表示。
Hims & Hers Health shares are under pressure on Thursday as the firm sells cheaper versions of the aforementioned drugs, known as compounded drugs. Hims & Hers said in May that it would begin selling compounded versions of GLP-1 injections. Shares surged on the news and have more than doubled since the start of the year.
Hims & Hers Health股價週四受壓，因該公司出售了所述藥物的廉價版本，被稱爲混合藥物。Hims & Hers在五月份表示將開始銷售GLP-1注射的混合版本。股價在這一消息公佈後飆升，並自年初以來翻了一番多。
Don't Miss: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
不容錯過：獨家報道：Tema etf首席執行官預測，GLP-1減肥藥物可能成爲萬億美元市場。
The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S (NYSE:NVO) sparked a demand boom for compounded drugs, which are made by combining, mixing, or altering drug ingredients, per Reuters.
來自禮來和競爭對手諾華醫藥 A/S(紐交所:NVO)的減肥和糖尿病藥物供應有限，這引發了混合藥物的需求激增，混合藥物是通過組合、混合或更改藥物成分製成的。
The report also indicates that regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. When there is no shortage, compounded drug makers are reportedly unable to make "regular or inordinate amounts" of the drugs.
該報告還指出，監管機構允許混合藥物進入市場以滿足需求，當出現藥物短缺時，報告稱，當沒有藥物短缺時，混合藥物製造商無法制造「普通或過量」的藥物。
Lilly reportedly began selling vials of its lowest dose of Zepbound in the U.S. directly to consumers via its website to help push back against the rise of compounded versions of the drug. Novo Nordisk's drugs were still listed on the FDA's shortage list as of Thursday.
據報道，禮來公司開始通過其網站直接向美國消費者銷售Zepbound最低劑量的小瓶，以幫助抵制藥品複方版本的崛起。截至週四，諾和諾德的藥品仍然被列入FDA短缺清單。
HIMS Price Action: Hims & Hers Health shares were down 8.92% at $17.26 at the time of publication, according to Benzinga Pro.
HIMS股價走勢：Hims & Hers Health股價在出版時爲17.26美元，根據Benzinga Pro的報道，下跌了8.92%。
Photo: Natalia Varlei from Shutterstock.
圖片：來自shutterstock的Natalia Varlei。
譯文內容由第三人軟體翻譯。
